NIGERIA— Biologix Support Services Ltd, a leading biotechnology company has been awarded ISO/IEC 17025:2017 certification from the Nigeria National Accreditation System (NiNAS).
Coinciding with the event of the certification was the launch of its new services and products in the diagnostic laboratory space.
The services will include a broad range of molecular diagnostic tests, DNA sequencing, and other pathology services.
The main scope of ISO certification is the accreditation of laboratories’ standards for testing and calibration that demonstrate competency, impartiality, and consistency to deliver global standards of services.
Biologix Support Services Ltd sets out to provide life science research and support services to the emerging biotechnology industry in Nigeria, according to the company.
Established a decade ago, the company aims to continue to provide its customers with excellent services that are designed to meet the demands of the fast-evolving biotechnology landscape.
Speaking at the formal event to unveil its new logo and biotech services, the Founder of Biologix Support Services Ltd, Dr. Voke Toye, said running a biotech company has been an exciting journey despite the hurdles during the humble beginnings.
She noted that her goal was to run something measurable with international standards. “Biologix has always used international benchmarks for all activities it carries out,” Dr. Voke stated.
The founder described the ISO/IEC 17025:2017 accreditation by the Nigeria National Accreditation System (NiNAS), new logos, and services as a significant milestone in the company’s journey towards becoming a leading biotechnology company in Nigeria and Africa.
According to the techcabal, Nigeria doesn’t contribute much to the global biotech industry which is estimated to be worth US$833.34 billion with a Compound Annual Growth Rate (CAGR) of over 7.02% by 2027.
Currently, the narrative is changing with organizations such as 54gene, a Nigerian biotech startup that has attracted US$20 million in funding from Silicon Valley venture capitalists.
The startup aims to build genetic data sets that make landmark discoveries, a reality to significantly improve diversity of genomic data used for the discovery, diagnosis, and treatment of disease
The impending growth of biotech in Nigeria has been aided by the COVID-19 pandemic which has accelerated investment in the field.
Strikingly, most of the biotechnology research has been done through or by the Nigeria Institute of Medical Research Laboratories in collaboration with national and international partnerships.
In the recent past, the Nigeria Institute of Medical Research Laboratories has collaborated with the Co-Creation Hub (CCHUB) to develop a digital tool to aid adherence to Tuberculosis medications.
Unfortunately, the chronic underfunding of their efforts has stifled most of their work and projects.
Attempts to plug this gap have garnered some private sector initiatives such as Human Hereditary and Health in Africa (H3Africa) which aid funding in genomic research for African scientists interested in this field from ideation to implementation.
Biologix will be tapping into this growing interest in biotechnology from the public and private sectors as it seeks to grow its services even beyond Nigeria.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
